Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from... von Geyer, C.E., Sikov, W.M., Huober, J., Rugo, H.S., Wolmark, N., O’Shaughnessy, J., Maag, D., Untch, M., Golshan, M., Lorenzo, J. Ponce, Metzger, O., Dunbar, M., Symmans, W.F., Rastogi, P., Sohn, J.H., Young, R., Wright, G.S., Harkness, C., McIntyre, K., Yardley, D., Loibl, S.

Volltext

Veliparib monotherapy following carboplatin/paclitaxel plus veliparib combination therapy in patients with germline BRCA-associated advanced breast cancer: results of exploratory a... von Han, H.S., Arun, B.K., Kaufman, B., Wildiers, H., Friedlander, M., Ayoub, J.P., Puhalla, S.L., Bach, B.A., Kundu, M.G., Khandelwal, N., Feng, D., Bhattacharya, S., Maag, D., Ratajczak, C.K., Diéras, V.

Volltext

Radiologically evident treatment effects in patients with glioblastoma (GBM) and its clinical implications von Gan, H.K., Murone, C., Wong, M., Fitt, G., Kennedy, E., Maag, D., Aldape, K.

Volltext

Positron Emission Tomography Imaging of Poststroke Angiogenesis von WEIBO CAI, GUZMAN, Raphael, LI, Zi-Bo, MAAG, Anne-Lise D, HORI, Nobutaka, HENG ZHAO, MOSELEY, Michael, STEINBERG, Gary K, XIAOYUAN CHEN, HSU, Andrew R, HUI WANG, KAI CHEN, GUOHUA SUN, GERA, Atul, CHOI, Raymond, BLISS, Tonya, LINA HE

Volltext

246 PARP inhibitors trap PARP1 onto damaged DNA via catalytic inhibition and not by an allosteric mechanism von Hopkins, T, Solomon, L, Shi, Y, Rodriguez, L, Donawho, C, DiGiammarino, E, Panchal, S, Olson, A, Stolarik, D, Osterling, D, Gao, W, Johnson, E, Maag, D

Volltext

Uncoupling of Initiation Factor eIF5B/IF2 GTPase and Translational Activities by Mutations that Lower Ribosome Affinity von Shin, Byung-Sik, Maag, David, Roll-Mecak, Antonina, Arefin, M.Shamsul, Burley, Stephen K., Lorsch, Jon R., Dever, Thomas E.

Volltext

RESULTS FROM A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF CRISPR-BASED THERAPY NTLA-2002 FOR HEREDITARY ANGIOEDEMA von Cohn, D., Gurugama, P., Magerl, M., Katelaris, C., Golden, A., Shah, M., Maag, D., Longhurst, H.

Volltext

CRISPR/CAS9 EDITING OF KLKB1 IN HEREDITARY ANGIOEDEMA PATIENTS: UPDATED Results: FROM A PHASE 1 STUDY von Cohn, D., Lindsay, K., Gurugama, P., Fijen, L., Petersen, R., Golden, A., Maag, D., Longhurst, H.

Volltext

Template/Primer Requirements and Single Nucleotide Incorporation by Hepatitis C Virus Nonstructural Protein 5B Polymerase von Zhong, W, Ferrari, E, Lesburg, C A, Maag, D, Ghosh, S K, Cameron, C E, Lau, J Y, Hong, Z

Volltext

IN VIVO CRISPR/CAS9 EDITING OF KLKB1 IN PATIENTS WITH HEREDITARY ANGIOEDEMA: A FIRST-IN-HUMAN STUDY von Longhurst, H., Fijen, L., Lindsay, K., Butler, J., Golden, A., Maag, D., Xu, Y., Cohn, D.

Volltext

Pirt, a Phosphoinositide-Binding Protein, Functions as a Regulatory Subunit of TRPV1 von Kim, Andrew Y., Tang, Zongxiang, Liu, Qin, Patel, Kush N., Maag, David, Geng, Yixun, Dong, Xinzhong

Volltext

MO31-2 Telisotuzumab vedotin monotherapy in patients with previously treated c-Met+ advanced non-small cell lung cancer von Horinouchi, Hidehito, Goldman, J.W., Moiseenko, F., Cicin, I., Filippova, E., Bar, J., Tomasini, P., Ocampo, C., Sullivan, D., Maag, D., Motwani, M., Jin, J., Camidge, D.R.

Volltext

398PRadiologically evident treatment effects in patients with glioblastoma (GBM) and its clinical implications von Gan, H K, Murone, C, Wong, M, Fitt, G, Kennedy, E, Maag, D, Aldape, K

Volltext

Veliparib monotherapy following carboplatin/paclitaxel plus veliparib combination therapy in patients with germline BRCA-associated advanced breast cancer: results of exploratory a... von Han, H.S, Arun, B.K, Kaufman, B, Wildiers, H, Friedlander, M, Ayoub, J.P, Puhalla, S.L, Bach, B.A, Kundu, M.G, Khandelwal, N, Feng, D, Bhattacharya, S, Maag, D, Ratajczak, C.K, Dieras, V

Volltext

325P Characteristics of patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer who achieved durable response in the phase III BROCADE3 study von Kaufman, B., Han, H., Arun, B., Wildiers, H., Friedlander, M., Ayoub, J-P., Puhalla, S., Maag, D., Feng, D., Fages, S., Dieras, V.C.

Volltext

OA15.04 Telisotuzumab Vedotin (teliso-v) Monotherapy in Patients With Previously Treated c-Met+ Advanced Non-Small Cell Lung Cancer von Camidge, D.R., Moiseenko, F., Cicin, I., Horinouchi, H., Filippova, E., Bar, J., Lu, S., Tomasini, P., Ocampo, C., Sullivan, D., Maag, D., Goldman, J.

Volltext

P47.03 Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met+ Advanced Non-Small Cell Lung Cancer: Stage 2 von Goldman, J., Moiseenko, F., Cicin, I., Horinouchi, H., Filippova, E., Bar, J., Lu, S., Tomasini, P., Ocampo, C., Sullivan, D., Maag, D., Motwani, M., Jin, J., Camidge, D.R.

Volltext

P60.12 Prevalence of c-Met overexpression (c-Met+) and Impact of Prior Lines of Treatment on c-Met Protein Expression in NSCLC von Motwani, M., Panchabhai, S., Bar, J., Girard, N., Bradbury, P., Lu, S., Jin, J., Hotson, A., Maag, D., Planchard, D., Camidge, D.R.

Volltext

274O Health-related quality of life (HRQoL) changes with veliparib in patients (pts) with metastatic or locally advanced breast cancer in the phase III BROCADE 3 study von Dieras, V., Arun, B., Han, H.S., Wildiers, H., Friedlander, M., Ayoub, J.P., Puhalla, S., Hudgens, S., Floden, L., Khandelwal, N., Benjamin, K., Kamalakar, R., Maag, D.

Volltext

119O Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative... von Loibl, S., Sikov, W., Huober, J., Rugo, H.S., Wolmark, N., O'Shaughnessy, J., Maag, D., Untch, M., Golshan, M., Lorenzo, J. Ponce, Metzger, O., Dunbar, M., Symmans, W.F., Geyer, C.

Volltext